What Anthera Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Thompson John Craig | President & CEO | Sep 20 | Open-market buy · P | +8,550 | $1.32 | +$11.3K | 19,848 |
| Thompson John Craig | President & CEO | Sep 07 | Open-market buy · P | +10,400 | $1.43 | +$14.9K | 11,298 |
| Truex Paul F | Director | Sep 07 | Open-market buy · P | +5,000 | $1.34 | +$6.7K | 16,793 |
| Olson Charles V | CHIEF TECHNOLOGY OFFICER | Jan 11 | Grant / award · A | +7,767 | $0.55 | +$4.27K | 17,519 |
| Thompson John Craig | Chief Executive Officer | Jan 11 | Grant / award · A | +7,190 | $0.55 | +$3.95K | 7,190 |
| Truex Paul F | Chief Executive Officer | Sep 20 | Gift · G | +5,008 | — | — | 94,345 |
| Truex Paul F | Chief Executive Officer | Sep 20 | Gift · G | −5,008 | — | — | 0 |
| Truex Paul F | Chief Executive Officer | Sep 20 | Exercise / conversion · M | +5,008 | $2.08 | +$10.4K | 5,008 |
| Olson Charles V | CHIEF TECHNOLOGY OFFICER | Jun 30 | Grant / award · A | +1,789 | $2.63 | +$4.71K | 9,752 |
| Mueller Brian | Director | Dec 23 | Exercise / conversion · M | +10,000 | $2.89 | +$28.9K | 10,000 |
| Hislop Colin | Chief Medical Officer | Nov 13 | Disclosed 10b5-1 sale · S | −12,500 | $5.31 | −$66.3K | 19,147 |
| Hislop Colin | Chief Medical Officer | Nov 13 | Exercise / conversion · M | +12,500 | $1.61 | +$20.1K | 31,647 |
| Hislop Colin | Chief Medical Officer | Nov 11 | Open-market sale · S | −5,000 | $5.38 | −$26.9K | 19,147 |
| Odink Debra | Chief Technology Officer | Oct 12 | Disclosed 10b5-1 sale · S | −1,205 | $6.15 | −$7.41K | 7,896 |
| Dickinson Klara | SVP & Chief Regulatory Office | Jun 30 | Grant / award · A | +12,500 | $1.49 | +$18.6K | 12,500 |
| Liu May | SVP, Finance & Administration | Jun 30 | Grant / award · A | +12,500 | $1.49 | +$18.6K | 32,302 |
| Truex Paul F | Chief Executive Officer | Jun 30 | Gift · G | −12,500 | — | — | 89,337 |
| Truex Paul F | Chief Executive Officer | Jun 30 | Other Transaction · J | +12,500 | — | — | 101,837 |
| Truex Paul F | Chief Executive Officer | Jun 30 | Other Transaction · J | −12,500 | — | — | 0 |
| Truex Paul F | Chief Executive Officer | Jun 30 | Grant / award · A | +12,500 | $1.49 | +$18.6K | 12,500 |
Loading...
